Posted by Michael Wonder on 22 Oct 2016
Deal or delay: NICE's new negotiating chip
20 October 2016 - With the UK's NHS facing a financial challenge that shows no signs of abating any time soon, NICE and NHS England have offered a way forward through the affordability challenge.
Speed of NICE decision-making and speed of implementation of positive NICE guidance on new medicines will be part of ‘agreements’ (deals to you and me) with the NHS.
The first deal is that NICE will offer a ‘fast track’ process when the cost per QALY looks convincingly to be below or around the £10,000 ($12,300) mark and costing less than £20 million ($24.6 m) in the first three financial years after launch.
NICE expects to produce draft guidance immediately after the EMA publishes the marketing authorisation. Funding would be provided 30 days after NICE guidance, not the usual 90 days.
